Study of CAR T Cells for Solid Tumors That Have Come Back
Part of Cancer clinical trials.
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has returned or not responded to at least two prior standard treatments.
- Your tumor has a PD-L1 expression of 1% or more.
- You have at least one tumor that can be measured on a scan.
- You are in generally good health (able to care for yourself, organs working well).
- You are not pregnant and agree to use birth control during and after treatment.
- You have not received any prior cell therapy from a donor.
- You do not have an active infection, autoimmune disease, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.